NCT02663024View on ClinicalTrials.gov

Study of Idursulfase-beta (GC1111) in Hunter Syndrome

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

June 30, 2020

Conditions
Mucopolysaccharidosis II
Interventions
BIOLOGICAL

idursulfase beta

IV, weekly infusion for 24 weeks

BIOLOGICAL

idursulfase

0.5 mg/kg, iv, weekly infusion for 24 weeks

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY